Idarubicin, cytarabine, etoposide (IA ± E) chemotherapy yielded superior survival, while azacitidine+venetoclax (AZA+VEN) regimens underperformed. The study was registered on the Chinese clinical trial registry (ChiCTR) platform (No. ChiCTR2500096484).

2 days ago

Clinical data • Retrospective data • Journal

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

TP53 mutation • FLT3 mutation • NPM1 mutation • KIT mutation • TET2 mutation

Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • idarubicin hydrochloride

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. (PubMed, Trials)

This study aims to demonstrate that ABC-14 regimen is non-inferior to "3 + 7" regimen in newly diagnosed AML induction therapy while overcoming AB resistance and reducing toxicity associated with "3 + 7". It seeks to provide a broadly applicable alternative induction strategy for AML.

3 days ago

Journal

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • MCL1 (Myeloid cell leukemia 1)

TP53 mutation • FLT3-ITD mutation

Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended

3 days ago

Trial suspension

Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV

CONFIDHENCE: Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC (clinicaltrials.gov)

P=N/A, N=8, Completed, iOMEDICO AG | Recruiting --> Completed | N=100 --> 8 | Trial completion date: Dec 2028 --> Jul 2025 | Trial primary completion date: Jun 2028 --> Jul 2025

3 days ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

azacitidine • Tibsovo (ivosidenib)

22P.205: Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)

P1, N=6, Active, not recruiting, Thomas Jefferson University | Phase classification: P1/2 --> P1

4 days ago

Phase classification

BCL2 (B-cell CLL/lymphoma 2)

Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (clinicaltrials.gov)

P2, N=44, Active, not recruiting, Groupe Francophone des Myelodysplasies | Recruiting --> Active, not recruiting

4 days ago

Enrollment closed

Venclexta (venetoclax) • azacitidine

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients (clinicaltrials.gov)

P2, N=20, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=40 --> 20 | Recruiting --> Terminated; The research center has conducted a more comprehensive study.

7 days ago

Enrollment change • Trial termination • Minimal residual disease

NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • NUP214 (Nucleoporin 214) • DEK (DEK Proto-Oncogene)

NPM1 mutation

Venclexta (venetoclax) • azacitidine • daunorubicin

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches. (PubMed, Hematology Am Soc Hematol Educ Program)

Post-HCT azacitidine may have a role for MRD-positive AML. In AML with FLT3-internal tandem duplication mutation, post-HCT gilteritinib and sorafenib can be evidence-based strategies to target MRD. In ALL, blinatumomab is a powerful tool to eradicate MRD in patients with Philadelphia (Ph)-positive or Ph-negative ALL; tyrosine kinase inhibitors are indicated for post-HCT management of Ph+ ALL. Despite these advances, the optimal duration and type of intervention still remain unknown for many patients with acute leukemia who have peri-HCT MRD.

7 days ago

Review • Journal

FLT3 (Fms-related tyrosine kinase 3)

FLT3-ITD mutation

sorafenib • Xospata (gilteritinib) • azacitidine • Blincyto (blinatumomab)

10d

GANCE: Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML (clinicaltrials.gov)

P2, N=25, Not yet recruiting, First Affiliated Hospital of Zhejiang University

10 days ago

New P2 trial

BCL2 (B-cell CLL/lymphoma 2)

Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine